<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35175447</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1434-9949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical rheumatology</Title>
          <ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis.</ArticleTitle>
        <Pagination>
          <StartPage>1709</StartPage>
          <EndPage>1718</EndPage>
          <MedlinePgn>1709-1718</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-022-06091-5</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to clarify the relationship between the changes of pancreatic size after glucocorticoid (GC) therapy and relapse in IgG4-related autoimmune pancreatitis (AIP).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We prospectively enrolled 205 newly diagnosed IgG4-related AIP patients. 145 patients were followed up for more than 3 years. These patients were divided into three groups according to the changes of pancreatic size after treatment of 6 months: pancreatic swelling, normal size, and pancreatic atrophy. Baseline clinical and laboratory parameters were compared among three groups. Kaplan-Meier survival analysis was performed in the 134 patients based on GC therapy. Besides, Cox regression analysis and logistic regression analysis were performed to identify risk factors associated with relapse and the potential variables affecting changes of pancreatic size after treatment.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Age at diagnosis, white blood cell count, and serum IgG1 level at baseline were significantly different among the three groups. After treatment of 6 months, the pancreas of most patients (n = 81, 55.9%) could return to normal size, while persistent pancreatic swelling was found in 24.1% patients (n = 35), and atrophy was observed in 20.0% of the patients (n = 29). Kaplan-Meier survival analysis presented patients with pancreatic swelling after 6 months of GC therapy were more likely to relapse in the follow-up of 3 years. Persistent pancreatic swelling after treatment and salivary gland involvement at baseline were independent risk variables associated with relapse in IgG4-related AIP patients, while GC-based therapy was a protective factor of relapse. Logistic regression analysis revealed that older age at diagnosis was associated with pancreatic atrophy and higher baseline serum IgG1 level was associated with pancreatic swelling after treatment of 6 months.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with persistent pancreatic swelling after GC-based therapy of 6 months were more likely to relapse in the follow-up of 3 years. Older age at diagnosis and higher baseline serum IgG1 level were potential variables associated with pancreatic atrophy or swelling after treatment of 6 months. Key Points • Patients with persistent pancreatic swelling after glucocorticoid-based therapy were more likely to relapse in IgG4-related autoimmune pancreatitis. • Older age at diagnosis was associated with pancreatic atrophy after glucocorticoid-based therapy. • Higher baseline serum IgG1 level was associated pancreatic swelling after glucocorticoid-based therapy.</AbstractText>
          <CopyrightInformation>© 2022. International League of Associations for Rheumatology (ILAR).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Peng</LastName>
            <ForeName>Linyi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Ruie</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jiaxin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jieqiong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Chenman</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology and Immunology, People's Hospital of Jiaozuo City, Jiaozuo, 454002, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fei</LastName>
            <ForeName>Yunyun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Xiaofeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Yamin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China. Gracemin_1001@aliyun.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-7808-9867</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China. zhangwen91@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Clin Rheumatol</MedlineTA>
        <NlmUniqueID>8211469</NlmUniqueID>
        <ISSNLinking>0770-3198</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081012" MajorTopicYN="Y">Autoimmune Pancreatitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atrophy</Keyword>
        <Keyword MajorTopicYN="N">IgG4-related autoimmune pancreatitis</Keyword>
        <Keyword MajorTopicYN="N">Relapse</Keyword>
        <Keyword MajorTopicYN="N">Swelling</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>12</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35175447</ArticleId>
        <ArticleId IdType="doi">10.1007/s10067-022-06091-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s10067-022-06091-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kamisawa T, Takuma K, Egawa N, Tsuruta K, Sasaki T (2010) Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 7(7):401–409</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2010.81</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimosegawa T, Chari ST, Frulloni L et al (2011) International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40(3):352–358</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e3182142fd2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuruma S, Kamisawa T, Kikuyama M et al (2019) Clinical characteristics of autoimmune pancreatitis with IgG4 related kidney disease. Adv Med Sci 64(2):246–251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.advms.2018.12.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naitoh I, Nakazawa T, Ohara H et al (2010) Clinical significance of extrapancreatic lesions in autoimmune pancreatitis. Pancreas 39(1):e1-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e3181bd64a1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khandelwal A, Inoue D, Takahashi N (2020) Autoimmune pancreatitis: an update. Abdom Radiol (New York) 45(5):1359–1370</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00261-019-02275-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong Y, D’Onofrio M, Hocke M et al (2018) Autoimmune pancreatitis: imaging features. Endoscopic ultrasound 7(3):196–203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/eus.eus_23_17</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umehara H, Okazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22(1):21–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0571-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 259408</Citation>
        </Reference>
        <Reference>
          <Citation>Rehnitz C, Klauss M, Singer R et al (2011) Morphologic patterns of autoimmune pancreatitis in CT and MRI. Pancreatol: Off J Int Assoc Pancreatology (IAP) [et al] 11(2):240–51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000327708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachou PA, Khalili K, Jang HJ, Fischer S, Hirschfield GM, Kim TK (2011) Ig-related sclerosing disease autoimmune pancreatitis and extrapancreatic manifestations. Radiograph a Rev Publication Radiol Soc North Am Inc 31(5):1379–402</Citation>
        </Reference>
        <Reference>
          <Citation>Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N (2003) Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98(12):2694–2699</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2003.08775.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa T, Kawashima H, Ohno E et al (2020) Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study. Endoscopy 52(11):978–985</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-1183-3583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano K, Tada M, Isayama H et al (2013) High alcohol consumption increases the risk of pancreatic stone formation and pancreatic atrophy in autoimmune pancreatitis. Pancreas 42(3):502–505</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0b013e31826b3984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda A, Shiomi H, Matsuda T et al (2014) The relationship between pancreatic atrophy after steroid therapy and diabetes mellitus in patients. Pancreatol : Off J Int Assoc Pancreatol (IAP) [et al] 14(5):361–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pan.2014.07.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada Y, Masuda A, Sofue K et al (2020) Prediction of pancreatic atrophy after steroid therapy using equilibrium-phase contrast computed tomography imaging in autoimmune pancreatitis. JGH Open : Open Access J Gastroenterol Hepatol 4(4):677–683</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jgh3.12316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yunyun F, Yu P, Panpan Z et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatol (Oxford) 58(1):52–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/key227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Y, Li JQ, Zhang PP et al (2019) Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med 286(5):542–552</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/joim.12942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Stone JH (2019) Management of IgG4-related disease. Lancet Rheumatol 1(1):e55–e65</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(19)30017-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M, Nojima M, Takahashi H et al (2015) Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatol (Oxford) 54(1):45–49</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keu228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart PA, Topazian MD, Witzig TE et al (2013) Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 62(11):1607–1615</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-302886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crosara S, D’Onofrio M, De Robertis R et al (2014) Autoimmune pancreatitis: multimodality non-invasive imaging diagnosis. World J Gastroenterol 20(45):16881–16890</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i45.16881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreel L, Sandin B (1973) Changes in pancreatic morphology associated with aging. Gut 14(12):962–970</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.14.12.962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kubota K, Iida H, Fujisawa T et al (2007) Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 66(6):1142–1151</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2007.06.059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano K, Tada M, Isayama H et al (2007) Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 56(12):1719–1724</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2006.115246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maire F, Le Baleur Y, Rebours V et al (2011) Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 106(1):151–156</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2010.314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T, Shimosegawa T, Okazaki K et al (2009) Standard steroid treatment for autoimmune pancreatitis. Gut 58(11):1504–1507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2008.172908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiokawa M, Kodama Y, Kuriyama K et al (2016) Pathogenicity of IgG in patients with IgG4-related disease. Gut 65(8):1322–1332</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2015-310336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima I, Yamada K, Fujii H et al (2012) Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol 22(6):859–870</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0589-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeki T, Kawano M, Mizushima I et al (2013) The clinical course of patients with IgG4-related kidney disease. Kidney Int 84(4):826–833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.2013.191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raissian Y, Nasr SH, Larsen CP et al (2011) Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol 22(7):1343–1352</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2011010062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima I, Yamamoto M, Inoue D et al (2016) Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study. Arthritis Res Ther 18(1):273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-016-1175-y</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
